BeyondSpring logo

BeyondSpringNASDAQ: BYSI

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

09 March 2017

Next earnings report:

29 November 2024

Last dividends:

N/A

Next dividends:

N/A
$65.29 M
-88%vs. 3y high
39%vs. sector
-vs. 3y high
-vs. sector
-114%vs. 3y high
8%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | Fri, 15 Nov 2024 14:30:00 GMT
$1.62-$0.11(-6.14%)

Dividend

No data over the past 3 years

Analysts recommendations

Institutional Ownership

BYSI Latest News

BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting
globenewswire.com11 November 2024 Sentiment: POSITIVE

In 30 metastatic NSCLC patients who progressed on PD-1/PD-L1 inhibitors, the triple IO combo regimen at median follow-up time of 11.5 months achieved a DCR of 89.3% and Median PFS of 8.6 months In 30 metastatic NSCLC patients who progressed on PD-1/PD-L1 inhibitors, the triple IO combo regimen at median follow-up time of 11.5 months achieved a DCR of 89.3% and Median PFS of 8.6 months

BYSI Sees Quick 5.39% Surge Amid Low Trading Volume
gurufocus.com02 October 2024 Sentiment: POSITIVE

BeyondSpring Inc. (BYSI, Financial) experienced a notable stock price increase of 5.39%, reaching $2.54 per share. The trading volume was 20,920 shares, with a turnover rate of 0.05% and a volatility of 10.37%.

BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024
globenewswire.com16 September 2024 Sentiment: POSITIVE

Median PFS at 8.63 months and Disease Control Rate of 89.5% in Previously Treated NSCLC Patients after Progression on PD-1/L1 Monotherapy or in Combination with Platinum Doublet Chemotherapy Median PFS at 8.63 months and Disease Control Rate of 89.5% in Previously Treated NSCLC Patients after Progression on PD-1/L1 Monotherapy or in Combination with Platinum Doublet Chemotherapy

BeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics
globenewswire.com16 May 2024 Sentiment: POSITIVE

FLORHAM PARK, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global biopharmaceutical company focused on developing new cancer treatments, announced that it held a virtual Research and Development (R&D) Day to discuss its main product Plinabulin, a dendritic cell (DC) maturation agent, in combination with other drugs to address unmet medical needs in cancer patients who have not responded to PD-1/PD-L1 inhibitors. The event also included updates on SEED Therapeutics, which uses a target protein degradation (TPD) platform for innovative molecular glue drug discovery, on May 15, 2024.

BeyondSpring to Participate in the R.W. Baird's 2023 Global Healthcare Conference
GlobeNewsWire07 September 2023 Sentiment: NEGATIVE

NEW YORK, Sept. 07, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company focused on using a groundbreaking technology platform for drug discovery and developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs, today announced that management will present and participate in the R.W. Baird's 2023 Global Healthcare Conference, taking place on September 12 to 13, 2023 in New York City.

What type of business is BeyondSpring?

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

What sector is BeyondSpring in?

BeyondSpring is in the Healthcare sector

What industry is BeyondSpring in?

BeyondSpring is in the Biotechnology industry

What country is BeyondSpring from?

BeyondSpring is headquartered in United States

When did BeyondSpring go public?

BeyondSpring initial public offering (IPO) was on 09 March 2017

What is BeyondSpring website?

https://beyondspringpharma.com

Is BeyondSpring in the S&P 500?

No, BeyondSpring is not included in the S&P 500 index

Is BeyondSpring in the NASDAQ 100?

No, BeyondSpring is not included in the NASDAQ 100 index

Is BeyondSpring in the Dow Jones?

No, BeyondSpring is not included in the Dow Jones index

When was BeyondSpring the previous earnings report?

No data

When does BeyondSpring earnings report?

The next expected earnings date for BeyondSpring is 29 November 2024